LIST OF PUBLICATIONS

Transcription

LIST OF PUBLICATIONS
UNITÉ DE RECHERCHE SUR LA SCHIZOPHRÉNIE
LISTE DES PUBLICATIONS ET PRÉSENTATIONS EN RAPPORT AVEC LE PROJET
SCHIZOPHRÉNIE ET GLUTATHION
I. Articles originaux
Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F. -glutamylglutamine and
taurine concentrations are decreased in the cerebrospinal fluid of untreated patients with schizophrenic disorders.
J. Neurochem., 65, 2652-2662, 1995
Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M.
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Europ.J.Neurosci., 12, 37213728, 2000
Rougemont M, Do KQ, Castagne V. A new model of glutathione deficit during development: effect of glutathione
deficit on lipid peroxidation in the rat brain. Journal of Neuroscience Research, 70, 774-783, 2002
Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione
deficit: implication for schizophrenia. Schizophr.Res., 62, 213-224, 2003
Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione levels and ascorbic acid associated with
dopamine uptake inhibition during rat’s development induce long-term cognitive deficit: relevance to schizophrenia.
Neurobiology of disease, 15, 93-105, 2004
Benz B, Grima G, Do KQ. Glutamate-induced homocysteic acid release from astrocytes: Possible implication in glianeuron signaling. Neuroscience, 124, 377-386, 2004
Do KQ, Benz B, Binns KE, Eaton SA, Salt TE. Release of homocysteic acid from rat thalamus following stimulation of
somatosensory afferents in vivo: evidence for glial participation in synaptic transmission. Neuroscience, 124, 387393, 2004
Castagne V, Cuenod M, Do KQ. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits
in rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience123;
821-834, 2004
Do KQ, Bovet P, Cuenod M: Schizophrenia: glutathione deficit as a new vulnerability factor for the disconnectivity
syndrome. Swiss Archive of Neurology and Psychiatry, 155(8), 375-385, 2004
Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impairment and hypofunction of NMDA receptors induced
by glutathione deficit: relevance to schizophrenia. Neuroscience, 137, 807-819, 2006
Cabungcal JH, Nicolas D, Kraftsik R, Cuenod M, Hornung JP*, Do KQ*. Glutathione deficit during development
induces anomalies in the rat anterior cingulate GABAergic processes: relevance to schizophrenia. Neurobiology of
Disease, 22, 624-637, 2006
*Authors equally responsible for this work
Tosic M, Gysin R, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, Matthey ML, Parnas J, Preisig M, Saraga M,
Solida A, Timm S, Wang AG, Werge T, Cuenod M, Do KQ. Schizophrenia and oxidative stress: Glutamate cysteine
ligase modifier as a susceptibility gene. The American Journal of Human Genetics, 79, 586-592 (2006)
1
Kovacs KA*, Steullet P*, Steinmann M, Do KQ, Magistretti PJ, Halfon O, Cardinaux JR. TORC1 is a calcium- and
cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA,
104, 4700-4705 (2007)
* The two first authors have contributed equally to this work
Cabungcal JH, Preissmann D, Delseth C, Cuenod M, Schenk F*, Do KQ*. Transitory glutathione deficit during early
brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia?.
Neurobiology of Disease, 26, 634-45 (2007)
* Authors equally responsible for this work
Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M,
Werge T, Cuenod M, Do KQ. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional
evidence. Proc Natl Acad Sci USA, 104, 16621-16626 (2007)
Jalili M, Lavoie S, Deppen P, Meuli R, Do KQ, Cuenod M, Hasler M, De Feo O, Knyazeva MG. Dysconnection
topography in schizophrenia revealed with state-space analysis of EEG. PLoS ONE, 2(10):e1059 (2007)
Lavoie S*, Murray MM*, Deppen P, Knyazeva M, Berk M, Boulat O, Bovet P, Conus P, Copolov D, Fornari E, Meuli
RA, Solida A, Vianin P, Cuenod M, Buclin T, Do KQ. A glutathione precursor, N-acetyl-cysteine, improves mismatch
negativity in schizophrenia patients. Neuropsychopharmacology 33:2187-99 (2008)
* The two first authors have contributed equally to this work
Steullet P, Lavoie S, Guidi R, Kraftzig R, Cuenod M, Do KQ. Intracellular glutathione deficit alters dopamine
modulation of L-type calcium channels via D2 and ryanodyne receptors. Free Radical Biology and Medecine, 44,
1042-1054 (2008)
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, OrdingJespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush A. N-acetyl Cysteine as a Glutathione Precursor for
Schizophrenia – A Double-Blind, Randomized, Placebo-Controlled Trial. Biol. Psy. 64, 361-368 (2008)
Knyazeva MG, Jalili M, Meuli R, Hasler M, De Feo O, Do KQ. Alpha rhythm and hypofrontality in schizophrenia. Acta
Psychiatrica Scandinavica, 118,188-99 (2008)
Gysin R, Riederer IM, Cuenod M, Do KQ*, Riederer BM*. Skin fibroblast model to study an impaired glutathione
synthesis: Consequences of a genetic polymorphism on the proteome. Brain Research Bulletin, 79, 46–52 (2009)
* Authors with equal responsibility
Lavoie S, Chen Y, Dalton TP, Gysin R, Cuenod M, Steullet P, Do KQ. Curcumin, quercetin, and tBHQ modulate
glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J
Neurochem. 108, 1410-22 (2009)
Butticaz C, Werge T, Beckmann JS, Cuenod M, Do KQ*, Rivolta C*. Mutation screening of the glutamate cysteine
ligase modifier (GCLM) gene in patients with schizophrenia. Psychiatr Genet. 19(4), 201-208 (2009)
* Authors with equal responsibility
Jalili M, Meul R, Do KQ, Hasler M, Crow TM, Knyazeva MG. Attenuated Asymmetry of Functional Connectivity in
Schizophrenia: A High-resolution EEG Study. Psychophysiology, 47(4), 706-716 (2010)
Steullet P, Cabungcal JH, Kulak A, Kraftzig R, Ying C, Dalton TP, Cuenod M, Do KQ. Chronic Redox Dysregulation
Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations and
Related Behaviors, J. Neurosci. 30(7), 2547-2558 (2010)
Kulak A, Duarte JMN, Do KQ, Gruetter R. Neurochemical profile of the developing mouse cortex determined by in
vivo H NMR spectroscopy at 14.1 T and the effect of recurrent anaesthesia. J.Neurochem. 115, 1466-1477 (2010)
2
Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, Polari A, Steullet P, Preisig M, Teichmann T,
Cuenod M, Do KQ. Genetic Dysregulation of Glutathione Synthesis Predicts Alteration of Plasma Thiol Redox Status
in Schizophrenia. Antioxidants & Redox Signaling, 15(7): 2003-2010 (2011)
Butticaz C, Gysin R, Cuenod M, Do KQ. Interaction of GAG trinucleotide repeat and C-129T polymorphisms impairs
expression of the glutamate-cysteine ligase catalytic subunit gene. Free Radical Biology & Medicine, 50, 617-623
(2011)
Lavoie S, Allaman I, Petit JM, Do KQ, Magistretti PJ. Altered glycogen metabolism in cultured astrocytes from mice
with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia. PLoS ONE, 6 (7), e22875 (2011)
Duarte JMN*, Kulak A*, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes
neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biological
Psychiatry, 71 (11), 1006-1014 (2012)
* The two first authors have contributed equally to this work
Kulak A, Cuenod M, Do KQ. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and
bipolar disorder. Behav Brain Res., 226 (2), 563-570 (2012)
Cammoun L, Gigandet X, Meskaldji D, Thiran JP, Sporns O, Do KQ, Maeder P, Meuli R, Hagmann P. Mapping the
human connectome at multiple scales with diffusion spectrum MRI. J Neurosci Methods, 203 (2), 386-397 (2012)
Carmeli C, Knyazeva MG, Cuenod M, Do KQ. Glutathione precursor, N-acetyl-cysteine, modulates EEG
synchronization in schizophrenia patients: a double-blind randomized placebo-controlled trial. PLoS ONE, 7 (2),
e29341 (2012)
Baumann PS, Cammoun L, Conus P, Do KQ, Marquet P, Meskaldji D, Meuli R, Thiran JP, Hagmann P. High b-value
diffusion-weighted imaging: A sensitive method to reveal white matter differences in schizophrenia. Psychiatry
Research: Neuroimaging, 201 (2), 144-151 (2012)
Kulak A, Steullet P, Cabungcal JH, Werge T, Ingason A, Cuenod M, Do KQ. Redox Dysregulation in the
Pathophysiology of Schizophrenia and Bipolar Disorder: Insights from Animal Models. Antioxidants & Redox
Signaling, 18 (12), 1428-1443 (2013)
Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-Life Insults Impair Parvalbumin Interneurons via
Oxidative Stress: Reversal by N-Acetylcysteine. Biological Psychiatry, 73 (6), 574-582 (2013)
Cabungcal JH, Steullet P, Morishita H, Kraftsik R, Cuenod M, Hensch TK, Do KQ. Perineuronal nets protect fastspiking interneurons against oxidative stress. Proc Natl Acad Sci USA, 110 (22), 9130-9135 (2013)
Baumann PS, Crespi S, Marion-Veyron R, Solida A, Thonney J, Favrod J, Bonsack C, Do KQ, Conus P. Treatment
and Early Intervention in Psychosis Program (TIPP-Lausanne): implementation of an early intervention programme
for psychosis in Switzerland. Early Interv Psychiatry, 7 (3), 322-328 (2013)
Fournier M, Ferrari C, Baumann PS, Polari A, Monin A, Bellier-Teichmann T, Pappan K, Wulff J, Cuenod M, Conus P,
Do KQ. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophrenia Bulletin, 40 (5),
973-983 (2014)
Aline Monin, Philipp S. Baumann, Alessandra Griffa, Lijing Xin, Ralf Mekle, Margot Fournier, Christophe Butticaz,
Magali Klaey, Jan-Harry Cabungcal, Pascal Steullet, Carina Ferrari, Michel Cuenod, Rolf Gruetter, Jean-Philippe
Thiran, Patric Hagmann, Philippe Conus, Kim Q. Do. Glutathione deficit impairs myelin maturation: relevance for
white matter integrity in schizophrenia patients. Molecular Psychiatry, doi: 10.1038/mp.2014.88. [Epub ahead of
print] (2014)
3
Jan Harry Cabungcal*, Danielle S. Counotte*, Eastman Lewis*, Hugo A. Tejeda, Patrick Piantadosi, Cameron
Pollock, Gwendolyn G. Calhoon, Elyse Sullivan, Echo Presgraves, Jonathan J. Kil, L. Elliot Hong, Michel Cuenod, Kim
Q Do*, Patricio O’Donnell. Juvenile antioxidant treatment prevents adult deficits in a developmental model of
schizophrenia. Neuron, 83 (5), 1073-1084 (2014) * Equal contribution
Duarte J.M., Do K.Q., Gruetter R. Longitudinal neurochemical modifications in the aging mouse brain measured in
vivo by (1)H magnetic resonance spectroscopy. Neurobiology of Aging, 35 (7), 1660-1668 (2014)
O'Donnell P, Do KQ, Arango C. Oxidative/Nitrosative stress in psychiatric disorders: are we there yet? Schizophrenia
Bulletin, 40 (5), 960-962 (2014)
Steullet P, Cabungcal JH, Cuenod M, Do KQ. Fast oscillatory activity in the anterior cingular cortex: dopaminergic
modulation and effect of perineuronal net loss. Front Cell Neurosci, doi: 10.3389/fncel.2014.00244. eCollection
(2014)
Rossier J, Bernard A, Cabungcal JH, Perrenoud Q, Savoye A, Gallopin T, Hawrylycz M, Cuenod M, Do KQ, Urban A,
Lein Ed S. Cortical fast-spiking parvalbumin interneurons enwrapped in the perineuronal net express the
metallopeptidases Adamts8, Adamts15 and Neprilysin. Molecular Psychiatry, doi: 10.1038/mp.2014.162. [Epub
ahead of print] (2014)
Griffa A, Baumann PS, Ferrari C, Do KQ, Conus P, Thiran JP, Hagmann P. Characterizing the connectome in
schizophrenia with diffusion spectrum imaging. Hum Brain Mapp, 36 (1), 354-366 (2015)
Morishita H, Cabungcal JH, Chen Y, Do KQ, Hensch TK. Prolonged period of cortical plasticity upon redox
dysregulation in fast-spiking interneurons. Biological Psychiatry, in press
II. Articles de revue
Do KQ, Cabungcal JH, Frank A, Gysin R, Steullet P, Cuenod M: Redox dysregulation, neurodevelopment and
schizophrenia, Curr Opin Neurobiol, 19:220–230, (2009)
Do KQ, Conus P, Cuenod M. Redox dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge
in psychiatric diseases prevention. World Review of Nutrition and Dietetics, Basel, Karger; Simopoulos AP, Milner JA
(eds): Personalized Nutrition, vol. 101, 131-153 (2010)
Philippe Conus, Kim Q. Do, Quel rôle pour les neurosciences dans l'amélioration du traitement de la phase précoce
des troubles psychotiques? Exemple de l'hypothèse de la dysrégulation glutathion/redox dans la schizophrénie,
L'information psychiatrique vol. 86, N°6, 484-492 (2010)
Kim Q. Do. Gènes, environnement et neurodéveloppement: le cas de la schizophrénie. Revue Médicale Suisse, 9:
1672-7 (2013)
Steullet P., Cabungcal J.H., Monin A., Dwir D., O’Donnell P., Cuenod M., Do K.Q. Redox dysregulation,
neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology?
Schizophrenia Research, doi: 10.1016/j.schres.2014.06.021. [Epub ahead of print] (2014)
III. Livres
Do K. Q., Bovet P., Cabungcal J.H., Conus P., Gysin R., Lavoie S., Steullet P. and Cuenod M., Redox dysregulation
in schizophrenia: Genetic susceptibility and pathophysiological mechanisms, Handbook of neurochemistry and
molecular neurobiology, 3rd edition, edited by A Lajtha, Vol 27. Editors D. C. Javitt, J.T. Kantrowitz, Springer, New
York, Vol. Schizophrenia, 286-311, 2009
4
Steullet P, Cabungcal JH, Kulak A, Cuenod M, Schenk F, Do KQ. Glutathione deficit in animal models of
schizophrenia. In: Animal Models Of Schizophrenia and Related Disorders, edited by P. O’Donnell, Humana Press,
New York, pp. 149-188, 2011
IV. Autres












Do KQ and Cuénod M: "Schizophrénie : la piste du glutathion", Magazine suisse de la recherche Horizons,
N° 35, p.8, 1997
Do KQ and Cuénod M: "Nouvelles recherches sur la biologie de la schizophrénie", Journal du Graap "Tout
Comme Vous", N° 69, 1999
Do KQ: "Neurosciences Psychiatriques à Cery", Rapport 2000 des Institutions Psychiatriques du Canton de
Vaud, p.15, 2000
Bovet P, Do KQ, and Cuenod M: "Clinique et biochimie de la schizophrénie: La convergence de deux
perspectives", L’information psychiatrique, Vol. 77 (3), p. 235, 2001
CHUV- Magazine, octobre 2003: "De nouveaux regards sur la schizophrénie"
L’Hebdo, 10 février 2005: "Une cause de la schizophrénie élucidée"
Le Temps, 2 octobre 2007: "Schizophrénie: l'origine génétique se précise"
24 Heures, Agefi, Tribune de Genève, octobre 2007: "Découverte génétique sur la schizophrénie"
Do KQ, Cuenod M: "La recherche biomédicale sur la schizophrénie", Le fait médical, N°71, août 2009
Diagonales, Mensuel romand de la santé mentale, N° 84, novembre-décembre 2011: "Neurobiologie et
schizophrénie – La piste du glutathion"
CHUV Magazine, Hiver 2013: "Percer ensemble les secrets de la schizophrénie"
Horizons, Le magazine suisse de la recherche scientifique N° 97, juin 2013: "Chercher pour aider les
autres"
V. Prof. Kim Do Cuénod – Conférences, séminaires & symposiums sur invitation (2008 – 2014)









Plenary Speaker, Neuroscience 2014 – 44th Annual Meeting of the Society for Neuroscience: "Genes and
Environment Interaction during Development: Redox Imbalance in Schizophrenia", 17 November 2014,
Washington DC, USA
Conference, Central Institute of Mental Health, Department of Psychiatry: "Oxidative stress, NMDA
hypofunction and neuroinflammation in schizophrenia: a translational approach", 7 October 2014,
Mannheim, Germany
Conference, Pfizer Inc., Neuroscience Research Unit, Psychiatry and Behavioral Disorders: "Oxidative stress
in psychosis: a translational approach towards new targets for stage specific treatment", 13 May 2014,
Cambridge, USA
Conference, Harvard Medical School, Department of Psychiatry: "Redox dysregulation in schizophrenia:
functional anomalies prevented by N-acetyl-cysteine in translational models", 12 May 2014, Boston, USA
Symposium (co-chair, speaker), Society of Biological Psychiatry, 69th Annual Scientific Meeting: "Redox
Dysregulation Affects Myelination And Parvalbumine Interneurons In Schizophrenia Models", 10 May 2014,
New York, USA
Symposium (speaker), Society of Biological Psychiatry, 69th Annual Scientific Meeting: "Redox
Dysregulation Models of Schizophrenia: Functional Anomalies Prevented By N-acetyl-cysteine", 8 May 2014,
New York, USA
Satellite Symposium (organizer, speaker) "Schizophrenia: could it be prevented?", Society of Biological
Psychiatry, 69th Annual Scientific Meeting: "Oxidative stress in psychosis: a translational approach", 7 May
2014, New York, USA
Conference, Kings College London, Institute of Psychiatry, Department of Psychosis Studies: "Search for
biomarkers and redox dysregulation in early psychosis: a translational approach", 28 April 2014, London,
UK
Inaugural Lesson, Lausanne University Hospital (CHUV): "Neurosciences et psychiatrie: le développement
du cerveau, toutes les chances et tous les risques", 8 April 2014, Lausanne, Switzerland
5






















Symposium (speaker), Swiss Society for Neuroscience, Annual Meeting: "Oxidative stress in psychosis: a
translational approach", 25 January 2014, Bern, Switzerland
Lecture, PhD course on "Advanced biomedical imaging methods and instrumentation", Center for
Biomedical Imaging (CIBM), Swiss Federal Institute of Technology (EPFL): "Multimodal imaging in humans
and animal models: towards early detection and novel drug targets in psychosis", 13 December 2013,
Lausanne, Switzerland
Workshop, Brocher Foundation, Neuroscience, Ethics and Law: New Challenges for Human Identity,
Freedom and Responsibility: "Neuroscience of the self in health and disease", 6 November 2013,
Hermance, Switzerland
Symposium (speaker), 2nd SFCNS Congress, Swiss Federation of Clinical Neuro-Societies: "Oxidative stress
in psychosis: a translational approach", 6 June 2013, Montreux, Switzerland
Symposium (speaker), Society of Biological Psychiatry, 68 th Annual Scientific Meeting: "The Perineuronal
Net Protects Fast-Spiking Parvalbumine Interneurons Against Oxidative Stress", 18 May 2013, San
Francisco, USA
Conference, Le Relais – Association genevoise de soutien aux proches de personnes souffrant de troubles
psychiques: "Schizophrénie: la recherche progresse", 13 May 2013, Geneva, Switzerland
Symposium (speaker), CINP Thematic Meeting, Pharmacogenomics and Personalised Medicine in
Psychiatry: "Redox imbalance in schizophrenia and its improvement by N-acetyl-cysteine", 21 April 2013,
Jerusalem, Israel
Seminar, Institute of Anatomy and Cell Biology, Università Cattolica del S. Cuore: "Redox dysregulation in
schizophrenia: a translational approach", 5 April 2013, Rome, Italy
Conference, l'îlot – Association vaudoise de proches de personnes souffrant de schizophrénie:
"Schizophrénie: la recherche progresse", 6 March 2013, Lausanne, Switzerland
Symposium (co-chair, speaker), The International College of Neuropsychopharmacology, 28th World
Congress: "Oxidative stress and the development of mental disorders", 5 June 2012, Stockholm, Sweden
Seminar, Mount Sinai School of Medicine, NY: "Redox Dysregulation, Neurodevelopment, and
Schizophrenia: A Translational Approach", 7 May 2012, New York, USA
Symposium (co-chair, speaker), Society of Biological Psychiatry, 67th Annual Scientific Convention and
Program: " Connectomic abnormalities in schizophrenia ", 3 May 2012, Philadelphia, USA
Symposium (speaker), 3rd Biennial Schizophrenia International Research Conference: “Role for Oxidative
Stress, Inflammation, and Misfolded Protein in the Early Pathology of Schizophrenia”, 16 April 2012,
Florence, Italy
Seminar, Collège de France, Neurological and psychiatric diseases: a developmental perspective:
"Schizophrenia: genes and environment interactions of redox control during development", 16 March 2012,
Paris, France
Conference, Laboratorium für Organische Chemie, Swiss Federal Institute of Technology (ETHZ):
"Schizophrenia and oxidative stress: towards new therapeutic targets", 23 November 2011, Zurich,
Switzerland
Symposium (chair), Society of Biological Psychiatry, 66 th Annual Scientific Convention and Program: "Neural
synchrony, oxidative stress and neuroinflammation in schizophrenia", 13 May 2011, San Francisco, USA
Conference, Fondation HorizonSud: "Aspects des neurosciences psychiatriques et perspectives", 20 April
2011, Marsens, Switzerland
Conference, Montreux International Business Club: "La schizophrénie: Que se passe-t-il dans le cerveau?
Où en est la recherche?", 18 April 2011, Montreux, Switzerland
Symposium (speaker), International Congress on Schizophrenia Research: "Oxidative stress and
schizophrenia: 1H-MRS at 14.1 T in developing mice with glutathione deficit", 6 April 2011, Colorado
Springs, USA
Symposium (speaker), International Congress on Schizophrenia Research: "Redox dysregulation in early
psychosis and relevant animal models", 5 April 2011, Colorado Springs, USA
Conference, International Congress on Schizophrenia Research: "Redox dysregulation and oxidative stress
affects parvalbumin interneurons and neural synchrony in anterior cingulate cortex during
neurodevelopment", 4 April 2011, Colorado Springs, USA
Conference, 4ème JIPEJAAD, Hôpital Sainte-Anne: "Régulation du stress oxydatif et schizophrénie: la
nutrigénétique dans la prévention de la psychose", 22 March 2011, Paris, France
6






















Conference, Lausanne University Hospital, Colloque du Département de Médecine Interne: "Nouveaux
aspects de la pathophysiologie de la schizophrénie: neurodéveloppement, stress oxydatif et perspectives
thérapeutiques", 17 March 2011, Lausanne, Switzerland
Conference, Swiss Federal Institute of Technology (EPFL), Bureau de l'Egalité: "Schizophrenia: a
translational research towards new treatment and prevention", 15 March 2011, Lausanne, Switzerland
Conference, Semaine du cerveau 2011: "Schizophrénie: recherche translationnelle", 15 March 2011,
Lausanne, Switzerland
Conference, Lausanne University Hospital, Après-midi de recherche DP: "Developmental animal model of
schizophrenia: Redox dysregulation as susceptibility factor", 18 February 2011, Lausanne, Switzerland
Conference, Lausanne University Hospital, Department of Psychiatry, Section "Eugène Minkowski":
"Schizophrénie, déséquilibre redox et neurodéveloppement", 19 January 2011, Lausanne, Switzerland
Workshop (speaker), Stanford University, hosted by Herzenberg Laboratory: "Basic and clinical science of
N-Acetylcysteine: achievements, plans and mechanistic insights", 22 – 23 November 2010, Stanford, USA
Conference, Lausanne University Hospital, Colloque des neurosciences cliniques: "Oxidative stress,
neurodevelopment and psychosis: genetic susceptibility, pathophysiology and therapy", 22 September
2010, Lausanne, Switzerland
Portes ouvertes de l’Unité de recherche sur la schizophrénie pour les associations de proches et la
fondation Alamaya, 8 June 2010, Lausanne, Switzerland
Symposium (speaker), Society of Biological Psychiatry, 65th Annual Scientific Convention: "Redox
dysregulation and oxidative stress affects parvalbumin interneurons and neural synchrony: a reverse
translational approach towards new drug targets", 23 May 2010, New Orleans, USA
Symposium (chair), Society of Biological Psychiatry, 65th Annual Scientific Convention: "Oxidative-stress and
inflammation in schizophrenia: from NMDA and parvalbumin-interneurons to drug targets", 20 – 22 May
2010, New Orleans, USA
Conference, Departamento de Saúde Mental, Faculdade de Medicina – UFMG: "Oxidative stress,
neurodevelopment and psychosis: genetic susceptibility, pathophysioloy and therapy", 14 May 2010, Belo
Horizonte, Brazil
Symposium, Association francophone pour le savoir (ACFAS), 78ème congrès: "Dérégulation du sytème
redox en schizophrénie: aspects génétiques, environnementaux, neuro-développementaux et
thérapeutiques", 11 May 2010, Montréal, Canada
Conference, Centre de recherche Fernand-Séguin de l'hôpital Louis-H. Lafontaine: "Biomarqueurs en
psychiatrie", 10 May 2010, Montréal, Canada
Conference, Centre de recherche de l'hôpital Maisonneuve-Rosemont: "Redox dysregulation and oxidative
stress affect parvalbumin interneurons and neural synchrony: a translational approach towards new drug
targets in schizophrenia", 10 May 2010, Montréal, Canada
Seminar, Module thématique de recherche: schizophrénie, Département de psychiatrie, CHUV:
"Schizophrénie et glutathion: recherche translationnelle", 30 April 2010, Lausanne, Switzerland
Conference, Rotary Club Pully: "La schizophrénie: que se passe-t-il dans le cerveau? Où en est la
recherche?", 2 March 2010, Pully, Switzerland
Seminar, Section Minkowski, Département de psychiatrie – CHUV: "Schizophrénie, déséquilibre rédox et
neurodéveloppement", 20 January 2010, Lausanne, Switzerland
Seminar, Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology: "Redox
dysregulation, neurodevelopment & schizophrenia: a reverse translational approach", 12 January 2010,
Zurich, Switzerland
Conference, Après-midi de recherche du Département de psychiatrie: "Developmental animal model of
schizophrenia: redox dysregulation as susceptibility factor", 11 December 2009, Lausanne, Switzerland
Seminar, CIBM Research Day: "MRI/MRS as translational tools for schizophrenia pathophysiology: clinical
trial with the glutathion precursor N-acetyl-cysteine in early psychosis", 26 November 2009, Lausanne,
Switzerland
Conference, Rotary Club Lausanne Léman: "Une recherche biomédicale sur la schizophrénie", 11 November
2009, Lausanne, Switzerland
Seminar, National Institutes of Health, Child Psychiatry Branch: "Oxidative stress, neurodevelopment and
schizophrenia: a reverse translational approach", 22 October 2009, Bethesda, USA
7






















Symposium, 3rd Congress of the International Society of Nutrigenetics/Nutrigenomics: "Redox
dysregulation and oxidative stress in schizophrenia: nutrigenetics as a challenge in psychiatric diseases
prevention", 21 – 23 October 2009, Bethesda, USA
Seminar, MTR schizophrénie: "Schizophrénie et glutathion: recherche translationnelle", 1 October 2009,
Lausanne, Switzerland
Symposium: Can a translational approach lead to novel diagnostic and therapeutic perspectives in
schizophrenia? (Chair); “Translational approach to schizophrenia psychopathology: New susceptibility
genes and treatment perspectives” (Speaker) 2nd European Conference on Schizophrenia Research (ECSR),
21 - 23 September 2009, Berlin, Germany
Seminar, Monday Seminar, Brain Research Institute, University of Zurich: "Redox dysregulation and
oxidative stress in schizophrenia: genetic susceptibility, pathophysiology and therapy", 14 September 2009,
Zurich, Switzerland
Conference, Association des proches des patients souffrant de schizophrénie, Synapsespoir: "La
schizophrénie: Que se passe-t-il dans le cerveau? Où en est la recherche?", 2 June 2009, Sion, Switzerland
Seminar, Aktuelle Trends in der Psychiatrie: "Translational approach to schizophrenia psychopathology:
new susceptibility genes and treatment perspectives", Universitäre Psychiatrische Dienste Bern,
Postgraduate –Weiterbildung, 28 May 2009, Bern, Switzerland
Symposium, Society of Biological Psychiatry, 64th Annual Scientific Convention & Meeting: "Glutathione
dysregulation and oxidative stress in schizophrenia: genetic susceptibility, pathophysiology and therapy", 14
– 16 May 2009, Vancouver, Canada
Seminar, Immunology Series Seminar, Department of Pediatrics Stanford University School of Medicine:
"Redox dysregulation and oxidative stress in schizophrenia: genetic susceptibility, pathophysiology and
therapy", 12 May 2009, Standford, CA, USA
Symposium, International Congress on Schizophrenia Research: "Developmental critical period in genetic
redox dysregulation: animal and human studies in schizophrenia", 1 April 2009, San Diego, USA
Conference, International Congress on Schizophrenia Research: "Early glutathione deficit impairs
parvalbumin expression in GABA interneurons and kainate-induced gamma oscillations", 30 March 2009,
San Diego, USA
Conference, Cercle du Marché: "Histoire d'une passion: une recherche biomédicale sur la schizophrénie", 24
March 2009, Vevey, Switzerland
Conference, GSH Group visit: "Schizophrenia research: better understanding for better treatment, from
"bed to bench" in psychiatry", 24 February 2009, Lausanne, Switzerland
Conference, Inner Wheel, Montreux-Vevey: "Une recherche biomédicale sur la schizophrénie: mieux la
comprendre pour mieux la traiter", 13 February 2009, Montreux, Switzerland
Seminar “Redox dysregulation in schizophrenia: genetic susceptibility, pathophysiology and therapeutic
trial”, 21.11.2008, Maryland Psychiatric Research Center, Baltimore, USA
Seminar “Redox dysregulation in schizophrenia”, 20.11.2008, University of Maryland, Baltimore, USA
Board Meeting “Translational approach towards Novel schizophrenia therapies”, ”, 5.11.2008, Lundbeck,
Copenhagen, Denmark
Seminar, “Redox dysregulation in schizophrenia”, 5.11.2008, Lundbeck, Copenhagen, Denmark
Symposium “The Brain Lipids Conference 2008 “, “The aetiological role of glutathione deficiency in the
vulnerability to schizophrenia”, 8 -11 September 2008, Oslo, Norway
5th International Meeting, Advances in antioxidants (trace elements, vitamins and polyphenols) : Molecular
mechanisms, nutritional and clinical aspects ; " Redox dysregulation and oxidative stress in schizophrenia",
11-15 October, 2008, Monastir- Sousse, Tunisia
XXVI CINP Congress, Symposium “ Functional consequences of prefrontal cortical interneuron deficits in
schizophrenia: Insight from animal models and human imaging”, " Redox dysregulation and oxidative stress
in schizophrenia: Genetic and functional anomalies of glutathione synthesis in patients and experimental
models involving GABA interneurons and NMDA receptors", 13-17 July 2008, Munich , Germany
Symposium "Current Theories of Schizophrenia", “Redox dysregulation and oxidative stress in
schizophrenia: genetic susceptibility, pathophysiology and therapeutic trial”, Max-Planck Institute for Brain
Research, Frankfurt, June 20, 2008
Conference: “Translational approach to schizophrenia psychopathology : new susceptibility genes and
treatment perspectives”, University Medical Centre Utrecht, Netherland, May 13, 2008
8


International conference “Psychopathology of schizophrenia: 100 years”, “Translational approach to
schizophrenia psychopathology : New susceptibility genes and treatment perspectives”, Lausanne, 24-26
April, 2008
14th Biennial Winter Workshop on Schizophrenia and Bipolar disorders,” Can glutathione deficit be a risk
factor in the disconnectivity syndrome?” Montreux 3rd-7th February 2008
9

Documents pareils

unit for research in schizophrenia update 2013–2014

unit for research in schizophrenia update 2013–2014 Presgraves E, Kil JJ, Hong LE, Cuenod M, Do KQ*, O’Donnell P*. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron, 83 (5), 1073-1084 (2014) * E...

Plus en détail

Schizophrénies et troubles délirants tardifs à l`âge avancé

Schizophrénies et troubles délirants tardifs à l`âge avancé mary psychiatric pathologies amongst the elderly. It is crucial to distin­ guish them from secondary psychotic disorders associated with physical illnesses, such as acute confusion and psychotic sy...

Plus en détail